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and prescriptions were summarized in natural units. Average
(95%CI) outpatient, inpatient and drug cost/patient for EBC
patients were estimated to be €1000 (780–1260), €1060 (800–
1300) and €2470 (2100–2840) respectively. For LRR patients the
corresponding ﬁgures were €274 (214–330), €2056 (1470–2600)
and €2160 (1600–2700). In MBC values averaged €260
(210–310), €1150 (850–1550) and €3470 (2800–4150) respec-
tively. Drug costs represented 23%, 40% and 29% of total treat-
ment costs/patient in EBC, LRR and MBC. Costs were highest
in MBC. CONCLUSIONS: Inpatient costs represent the highest
proportion of costs, followed closely by drug costs, possibly due
to relatively low labour costs in Central Europe. These estimates
and underlying treatment patterns will be useful in establishing
the cost-effectiveness of new BC treatments in Hungary and
potentially in the region.
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The Finnish rheumatoid arthritis (RA) combination therapy
(FIN-RACo) trial has shown better efﬁcacy of three disease-
modifying antirheumatic drugs (DMARD) (sulphasalazine,
methotrexate, hydroxychloroquine) and prednisolone compared
to treatment with a single DMARD with or without pred-
nisolone in early RA. Results from FIN-RACo trial show that
early aggressive combination therapy (COMBI) translated into
more remissions and less peripheral joint damage, cervical spine
subluxations, and work disability than therapy with a single
DMARD (SINGLE). OBJECTIVES: Estimate health-related
quality of life (HRQoL) effects of COMBI vs. SINGLE in early
RA. METHODS: A total of 195 patients with early RA were
randomised to COMBI (n = 97) or SINGLE (n = 98) for 2 years.
Thereafter drug treatment became unrestricted. HRQoL was
measured using the 15D instrument. The 15D score of an addi-
tional control sample was used as an estimate of baseline
HRQoL in early RA. RESULTS: The baseline 15D score was
0.856 (95% CI 0.835–0.877; n = 49). The respective ﬁve and
10–11 years 15D scores of COMBI were signiﬁcantly better than
the baseline score (0.929; n = 28, p = 0.000 and 0.901; n = 39,
p = 0.002), in contrast to the corresponding scores of SINGLE
(0.880; n = 34, p = 0.078 and 0.858; n = 30, p = 0.900). The
differences between the COMBI and SINGLE scores at 5 and
10–11 years reached statistical signiﬁcance (p = 0.017 and
0.046), too. CONCLUSION: Early aggressive treatment with
combination of DMARDs is effective also from the viewpoint of
HRQoL. The effect sustains at least up to 10–11 years.
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OBJECTIVES: To evaluate whether it is accepted that commu-
nity pharmacies identify elderly people which are at risk for
osteoporosis and furthermore evaluate the effectiveness of com-
munity pharmacies to motivate identiﬁed patients at risk for
osteoporosis to consult a physician for further diagnosis and
treatment. METHODS: Prospective multi-centre pre-post evalu-
ation in 20 community pharmacies in Southern Germany includ-
ing 765 patients. The screening for risk for osteoporosis 
was based on an adapted osteoporosis risk-questionnaire of 
the “Kuratorium Knochengesundheit e.V.—German Self-Help-
Group”. Patients with identiﬁed risk were consulted with regard
to the disease osteoporosis and recommended to see a physician
for further diagnosis. A maximum of 2 follow-up contacts were
undertaken to receive information whether or not a physician
was seen by the patient. RESULTS: Out of 765 patients, which
were interviewed using the osteoporosis risk-questionnaire 53%
were identiﬁed being at risk and thus were requested to contact
their physician. 66% of these patients did respond to the rec-
ommendation by the community pharmacy and did see a physi-
cian for consultation and further diagnosis of osteoporosis. As a
result, an anti-osteoporotic pharmacotherapy was initiated in
33% of those patients who saw a physician. Overall, 57% of
patients indicated their satisfaction with the service provided by
the pharmacy and 64% agreed that a community pharmacy is
an appropriate place to offer screening for osteoporosis. CON-
CLUSION: Community pharmacies are easy to access by elderly
people and a screening for osteoporosis using an osteoporosis
screening risk-questionnaire was accepted by the majority of
patients.
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OBJECTIVES: How GPs reacted to rofecoxib withdrawal in
Sept. 30, 2004. METHODS: A drug utilisation review was 
performed using data from the electronic records of 1200 French
GPs. All patients aged 65 years and over, suffering from
osteoarthritis and who were prescribed any COX-2 between
January 1st and September 30th 2004 (“reference period”) were
included and compared to themselves in the same period of 2005
(“observation period”). Patients were classiﬁed either as “con-
tinuers” if they received at least one COX-2 prescription in the
“observation period”, or as “stoppers” if not. Discriminatory
factors between the two groups were systematically searched for.
RESULTS: A total of 5589 patients were included. Mean age was
75 years and 68.2% were female. A total of 811 (14.5%) were
classiﬁed as “continuers” and 4778 (85.5%) as “stoppers”.
Among the latter 2914 (61.0%) stopped any NSAID treatment
and 955 (19.9%) received no treatment at all (neither NSAID
